Guardant Health (NASDAQ:GH) is a pioneering company focused on conquering cancer with its ground-breaking blood tests, vast data sets, and analytics. Their operations span from developing and commercializing oncology diagnostic products and services, which enable more accurate therapeutics, to providing comprehensive genomic profiling assays that support clinical development, prevention, and early detection of cancer. Guardant Health's significant projects include the Guardant360 and GuardantOMNI tests for advanced stage cancer patients and the LUNAR assay for research use and early cancer detection. With a mission to improve patient outcomes and increase the efficiency of cancer care, Guardant Health is at the forefront of driving forward precision oncology. The company is traded on the NASDAQ stock market under the ticker code (NASDAQ:GH), reflecting its commitment to innovation and leadership in the healthcare sector.